Press Releases

 
Press Releases
Date Title and Summary View
May 9, 2014 SALT LAKE CITY, May 9, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, president and CEO of Myriad, is scheduled to present at the Bank of America Merrill Lynch 2014 Health Care Conference, at 10:00 a.m. Pacific on May 13, 2014, at the Encore at the Wynn in Las Vegas, Nevada. The presentat...
May 6, 2014 SALT LAKE CITY, May 6, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced financial results for the fiscal third quarter and nine months ended March 31, 2014, increased its fiscal year 2014 guidance, and provided an update on recent business highlights. Revenue for the third quarter was $182.9 million, a 17 percent increas...
May 6, 2014 SALT LAKE CITY, May 6, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it has signed a three-year contract with UnitedHealthcare. The contract provides UnitedHealthcare with access for BRCA testing and the myRisk Hereditary Cancer test for patients who meet the hereditary cancer testing eligibility criteria. My...
May 1, 2014 SALT LAKE CITY, May 1, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced clinical data from three studies on Prolaris in prostate cancer patients will be featured at the 2014 American Urological Association (AUA) Annual Meeting, being held May 16-21, 2014, in Orlando, Fla. Prolaris is a novel molecular diagnostic test tha...
Apr 22, 2014 SALT LAKE CITY, April 22, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the third fiscal quarter of 2014 following the close of market on Tuesday, May 6, 2014. The Company also will host a conference call on Tuesday, May 6, 2014 at 4:30 p.m. ET to discuss the financial ...
Apr 7, 2014 SALT LAKE CITY, April 7, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has submitted the first module of a premarket approval (PMA) application to the Food and Drug Administration (FDA) for the use of BRACAnalysis® testing as a companion diagnostic with olaparib. Olaparib is an investigational, orally act...
Mar 25, 2014 SALT LAKE CITY, March 25, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that results from seven clinical studies will be presented at the upcoming American College of Medical Genetics (ACMG) annual meeting, which will be held Mar. 25-Mar.29, 2013 in Nashville, Tennessee. "We believe clinical research is vital ...
Mar 24, 2014 SALT LAKE CITY, March 24, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that Tesaro, Inc. will use Myriad's novel HRD (homologous recombination deficiency) test to identify tumor types that may respond to its investigational poly-ADP ribose polymerase (PARP) inhibitor, niraparib, currently in Phase 3 clinical developm...
Mar 20, 2014 PARIS and SALT LAKE CITY, March 20, 2014 (GLOBE NEWSWIRE) -- Institut Pasteur and Myriad RBM, a wholly-owned subsidiary of Myriad Genetics, Inc., today announced they have published an initial data analysis from the landmark Milieu Interieur Project in the journal Immunity, which provided new insights into the healthy human immune response. The Mil...
Mar 20, 2014 SALT LAKE CITY, March 20, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today noted that the Society of Gynecologic Oncology (SGO) has issued new clinical practice statements surrounding hereditary cancer testing for patients with ovarian and endometrial cancer. The statements are consistent with the recently revised National Compreh...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase